Most Recent Articles by Leslie Burgess, MA
Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.
Cancer Therapy Advisor interviewed Keith Flaherty, MD, about recent findings regarding targeted therapies for melanoma.
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
Patients with relapsed or refractory MCL treated with ibrutinib had longer PFS with less toxicity than patients treated with temsirolimus in a phase 3 trial.
A new study provided firm evidence for the benefit of S-1 in treatment of patients with metastatic breast cancer (mBC).
More Articles by Leslie Burgess, MA
Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of NeurotoxicityAug 25,2015
Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk DiseaseSep 17,2014
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer
- FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective